South Korea Inflation Edges Up in November as Food and Service Costs Climb 
Dollar Slips as Weak U.S. Manufacturing Data Increases Pressure for Fed Rate Cuts 
Oil Prices Rise as Geopolitical Tensions and Supply Risks Intensify 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Dollar Holds Steady as Markets Shift Focus to 2026 Rate Cut Expectations 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
South Korea Posts Stronger-Than-Expected 1.3% Economic Growth in Q3 
Tech Stocks Lift S&P 500 as Fed Rate-Cut Expectations Rise 
U.S. Stocks Slip as Investors Await Fed Rate Decision and Monitor Market Shifts 
Trump Administration Plans Major Rollback of Biden-Era Fuel Economy Standards 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
China has approved Eli Lilly’s Kisunla, marking another milestone in global efforts to address Alzheimer’s disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a unique dosing approach and new hope for managing the disease.
China Approves Kisunla as a New Alzheimer's Treatment Option
After Eisai and Biogen's Leqembi were approved in January, Eli Lilly said late Tuesday that their treatment for early Alzheimer's has been approved by China's medical authorities, giving patients another alternative, Reuters reports.
According to a statement from Lilly, the medication, which is marketed under the trade name Kisunla, has been approved in four key markets: the US, Japan, and the UK. The latest addition to this list is China.
In the same way as Leqembi removes beta-amyloid from the brain, Lilly's Kisunla does the same.
Kisunla Shows Promising Results in Cognitive Decline
Kisunla shown a 29% reduction in the development of cognitive impairments as compared to a placebo in a large, late-stage experiment. Although most occurrences were moderate, it did induce brain edema in approximately 25% of patients and brain bleeding in approximately 33%.
In the United States, the prescribing label for Kisunla bears the FDA's most severe "boxed" safety warning, which, like Leqembi, warns of the possibility of fatal brain enlargement and hemorrhage.
Gradual Dosing and Finite Treatment Benefit Kisunla Users
However, the business reported that the number of patients having potentially significant brain swelling was reduced when Kisunla was started on a more gradual dose schedule.
Another advantage of Kisunla over Leqembi is its finite dosage, which lets patients discontinue treatment once brain scans reveal no more amyloid plaques.
The medicines authority of the European Union is presently evaluating the treatment. In July, the body decided against using Leqembi because the potential for severe brain swelling was not worth the minimal benefit in preventing cognitive loss, Investing.com shares.
Alzheimer’s Drives Majority of Dementia Cases Globally
The World Health Organization reports that between sixty percent and seventy percent of dementia cases are caused by Alzheimer's disease.
